Copy Number Gains of FGFR1 and 3q Chromosome in Squamous Cell Carcinoma of the Lung

Overview

Journal Transl Lung Cancer Res

Date 2015 Mar 26

PMID 25806221

Citations 8

Authors

Pedro Mendez

Jose Luis Ramirez

Affiliations

Soon will be listed here.

Abstract

Squamous cell carcinoma of the lung (SQCCL) remains a leading cause of cancer-related death. Unlike non-smoker adenocarcinoma of the lung, where highly efficient tyrosine kinase inhibitors are available for treating mutant EGFR or ALK-rearranged, no targetable biomarkers are available for SQCCL. The frequent and focal amplification of FGFR1 has generated great expectations in offering new therapeutical options in case of 16-22% of SQCCL patients. Broad 3q chromosome amplification is widely recognized as the most common chromosomal aberration found in SQCCL, where PIK3CA, SOX2, ACK1, PRKCI, TP63, PLD1, ECT2, and others genes are located. Although SOX2 has been postulated as a key regulator of basal stem cells transformation and tumor progression, it seems to confer a good prognosis in SQCCL. It is known that each patient might carry a different length of 3q chromosome amplicon. Thus, we suggest that the number and the biological importance of the genes spanned along each patient's 3q amplicon might help to explain inter-individual outcome variations of the disease and its potential predictive value, especially when relevant oncogenes such as those mentioned above are implicated. Currently, there is no clinical predictive data available from clinical trials. In this review, we have focused on the potential role of FGFR1 in SQCCL prognosis. Additionally, we have explored recently available public data on the comprehensive genomic characterization of SQCCL, in relation to the protein-coding genes that have a strong gene copy number - mRNA correlation in 3q chromosome, that were previously described as potential driver oncogenes or its modifiers in SQCCL.

Citing Articles

Somatic loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study.

Fang Z, Wu X, Xiao L, Wang C, Zhao Y, Zhang Q J Thorac Dis. 2024; 16(5):3338-3349.

PMID: 38883659 PMC: 11170359. DOI: 10.21037/jtd-24-134.

Single-cell data analysis of malignant epithelial cell heterogeneity in lung adenocarcinoma for patient classification and prognosis prediction.

Ran X, Tong L, Chenghao W, Qi L, Bo P, Jiaying Z Heliyon. 2023; 9(9):e20164.

PMID: 37809682 PMC: 10559937. DOI: 10.1016/j.heliyon.2023.e20164.

Moving pan-cancer studies from basic research toward the clinic.

Chen F, Wendl M, Wyczalkowski M, Bailey M, Li Y, Ding L Nat Cancer. 2022; 2(9):879-890.

PMID: 35121865 DOI: 10.1038/s43018-021-00250-4.

Identification of an ACK1/TNK2-based prognostic signature for colon cancer to predict survival and inflammatory landscapes.

Kong D, Li G, Yang Z, Cheng S, Zhang W, Feng L BMC Cancer. 2022; 22(1):84.

PMID: 35057760 PMC: 8772074. DOI: 10.1186/s12885-021-09165-w.

Multi-Omics Analysis of the Effects of Smoking on Human Tumors.

Wang R, Li S, Wen W, Zhang J Front Mol Biosci. 2021; 8:704910.

PMID: 34796198 PMC: 8592943. DOI: 10.3389/fmolb.2021.704910.

References

Courjal F, Cuny M, Simony-Lafontaine J, Louason G, SPEISER P, Zeillinger R . Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997; 57(19):4360-7. View

Regala R, Weems C, Jamieson L, Copland J, Thompson E, Fields A . Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem. 2005; 280(35):31109-15. DOI: 10.1074/jbc.M505402200. View

Agulnik M, Giel J . Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor. Am J Clin Oncol. 2012; 37(4):417-22. DOI: 10.1097/COC.0b013e31824be3d6. View

Travis W . Pathology of lung cancer. Clin Chest Med. 2011; 32(4):669-92. DOI: 10.1016/j.ccm.2011.08.005. View

Pao-Chun L, Chan P, Chan W, Manser E . Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling. J Biol Chem. 2009; 284(50):34954-63. PMC: 2787358. DOI: 10.1074/jbc.M109.072660. View

Kim H, Kim D, Kang D, Lee J, Lim S, Lee C . Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol. 2012; 31(6):731-7. DOI: 10.1200/JCO.2012.43.8622. View

Melino G . p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 2011; 18(9):1487-99. PMC: 3178431. DOI: 10.1038/cdd.2011.81. View

Yamamoto H, Shigematsu H, Nomura M, Lockwood W, Sato M, Okumura N . PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008; 68(17):6913-21. PMC: 2874836. DOI: 10.1158/0008-5472.CAN-07-5084. View

Frederick M, VanMeter A, Gadhikar M, Henderson Y, Yao H, Pickering C . Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol. 2011; 178(2):548-71. PMC: 3070553. DOI: 10.1016/j.ajpath.2010.10.044. View

10.

Schildhaus H, Heukamp L, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E . Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012; 25(11):1473-80. PMC: 4089812. DOI: 10.1038/modpathol.2012.102. View

11.

Kelley L, Weed S . Cortactin is a substrate of activated Cdc42-associated kinase 1 (ACK1) during ligand-induced epidermal growth factor receptor downregulation. PLoS One. 2012; 7(8):e44363. PMC: 3431376. DOI: 10.1371/journal.pone.0044363. View

12.

Mahajan K, Mahajan N . PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol. 2012; 227(9):3178-84. PMC: 3358464. DOI: 10.1002/jcp.24065. View

13.

Theillet C, Adelaide J, Louason G, Jacquemier J, Adnane J, Longy M . FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer. 1993; 7(4):219-26. DOI: 10.1002/gcc.2870070407. View

14.

Ng K, Hillmer A, Chuah C, Juan W, Ko T, Teo A . A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18(4):521-8. DOI: 10.1038/nm.2713. View

15.

Mason I . Initiation to end point: the multiple roles of fibroblast growth factors in neural development. Nat Rev Neurosci. 2007; 8(8):583-96. DOI: 10.1038/nrn2189. View

16.

Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L . FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012; 2(12):1118-33. DOI: 10.1158/2159-8290.CD-12-0210. View

17.

Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C . Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2006; 43(1):60-6. DOI: 10.1016/j.oraloncology.2006.01.005. View

18.

Loffler H, Fechter A, Matuszewska M, Saffrich R, Mistrik M, Marhold J . Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance. Cancer Res. 2011; 71(6):2129-39. DOI: 10.1158/0008-5472.CAN-10-2684. View

19.

Yano S, Takeuchi S, Nakagawa T, Yamada T . Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci. 2012; 103(7):1189-94. PMC: 7659280. DOI: 10.1111/j.1349-7006.2012.02279.x. View

20.

Erdogan E, Klee E, Thompson E, Fields A . Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma. Clin Cancer Res. 2009; 15(5):1527-33. PMC: 3260476. DOI: 10.1158/1078-0432.CCR-08-2459. View